Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other Accumulated Expenses (2018 - 2025)

10x Genomics (TXG) has disclosed Other Accumulated Expenses for 8 consecutive years, with $23.4 million as the latest value for Q4 2025.

  • Quarterly Other Accumulated Expenses changed N/A to $23.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $23.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at $23.4 million for FY2025, N/A changed from the prior year.
  • Other Accumulated Expenses hit $23.4 million in Q4 2025 for 10x Genomics, down from $23.7 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $23.7 million in Q3 2025 to a low of $197000.0 in Q2 2021.
  • Historically, Other Accumulated Expenses has averaged $7.8 million across 5 years, with a median of $5.5 million in 2024.
  • Biggest five-year swings in Other Accumulated Expenses: crashed 99.74% in 2021 and later soared 2398.98% in 2022.
  • Year by year, Other Accumulated Expenses stood at $8.3 million in 2021, then fell by 19.05% to $6.7 million in 2022, then plummeted by 34.2% to $4.4 million in 2023, then grew by 29.59% to $5.7 million in 2024, then soared by 308.52% to $23.4 million in 2025.
  • Business Quant data shows Other Accumulated Expenses for TXG at $23.4 million in Q4 2025, $23.7 million in Q3 2025, and $12.8 million in Q2 2025.